Business
OTC Markets Group Welcomes Rasna Therapeutics to OTCQX
OTC Markets Group Welcomes Rasna Therapeutics to OTCQX.
About this update from Actavia Life Sciences, Inc.
[{"type":"text","content":"\n\n\n\nOTC Markets Group Welcomes Rasna Therapeutics to OTCQX\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOTC Markets Group Welcomes Rasna Therapeutics to OTCQX\nPR Newswire\nNEW YORK, April 12, 2017\n\n\n\nNEW YORK, April 12, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Rasna Therapeutics, Inc. (OTCQX: RASP), a clinical-stage  biotechnology company focused on delivering novel therapeutics and biomarkers for acute myeloid leukemia (AML) patients, has qualified to trade on the OTCQX® Best Market.  Rasna Therapeutics upgraded to OTCQX from the OTCQB® Venture Market.   \n\nRasna Therapeutics begins trading today on OTCQX under the symbol \"RASP.\"  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.\n\n\"Congratulations to Rasna Therapeutics on upgrading to the OTCQX market from OTCQB,\" said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. \"OTCQX companies meet high financial standards, follow corporate governance best practices and are distinguished by the integrity of their operations. We look forward to supporting Rasna Therapeutics and its shareholders.\"\n\n\"The uplisting of Rasna Therapeutics to OTCQX is an important stepping stone on our development path,\" commented Alessandro Padova, Chairman of Rasna Therapeutics. \"As we look to expand our portfolio of therapeutics under development, our entry into a more liquid market should provide the benefits of access to a broader pool of capital and greater visibility within the financial community.\"\n\nRasna Therapeutics was sponsored for OTCQX by Sheppard, Mullin, Richter & Hampton LLP, a qualified 3rd party firm responsible for providing guidance on OTCQX requirements and recommending membership.  \n\nRasna Therapeutics, Inc. is a biotechnology company focused primarily on the high unmet need that exists for leukemias. Rasna's primary indication is acute myeloid...